Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...

The pharmaceutical giant Eli Lilly has once again raised the bar in the highly competitive obesity treatment market. New clinical trial data for its experime ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

Eli Lilly's "triple g" drug helped patients lose about 28.7% of their body weight while also reducing pain associated with knee osteoarthritis in a Phase 3 trial. One of Eli Lilly's most promising new ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY) announced Monday that it will present results from two Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia (CLL) at the upcoming ...

Eli Lilly reported the first successful phase three results for retatrutide, its experimental once-weekly ‘triple agonist’ ...

Researchers monitoring the brain activity of a patient with a severe binge-eating problem reported that Eli Lilly’s GLP-1 weight-loss drug appeared to temporarily suppress food-craving signals in the ...

Brain monitoring shows tirzepatide reduces food cravings Binge-eating signals were suppressed in the nucleus accumbens, the brain's reward center Effect seen in a single patient was only temporary GLP ...

LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer ...

Under the partnership, Lilly will pay IU up to $40 million to build clinical trial infrastructure, accelerate access to ...